We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression ( 535 patients ) , to the same combination for 72 weeks ( 18 cycles ; 541 patients ) , or to MPT for 72 weeks ( 547 patients ) .